Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Bristol-Myers Squibb ( (BMY) ) has issued an update.
On April 30, 2026, Bristol Myers Squibb reported first-quarter 2026 results showing total revenue of $11.5 billion, up 3% year on year (1% excluding currency), driven by a 12% rise in its Growth Portfolio to $6.2 billion, while its Legacy Portfolio fell 6% amid expected generic erosion. GAAP earnings per share rose 9% to $1.31, non-GAAP EPS declined 12% to $1.58, and management reaffirmed full-year 2026 guidance, signaling confidence that strong demand for newer therapies and an advancing pipeline can offset legacy headwinds and support performance toward the upper end of revenue and earnings targets.
The company highlighted robust international sales growth of 11% (4% ex-FX), contrasting with a 1% decline in U.S. revenue, underscoring a shifting geographic mix as products like Camzyos, Breyanzi and Reblozyl deliver double-digit gains worldwide. By posting detailed financial and operating materials alongside its earnings call, Bristol Myers Squibb aimed to emphasize disciplined execution and a strengthened foundation ahead of pivotal data readouts, reinforcing its strategic narrative to investors that pipeline progress and growth brands are increasingly central to its long-term value proposition.
The most recent analyst rating on (BMY) stock is a Buy with a $75.00 price target. To see the full list of analyst forecasts on Bristol-Myers Squibb stock, see the BMY Stock Forecast page.
Spark’s Take on BMY Stock
According to Spark, TipRanks’ AI Analyst, BMY is a Outperform.
The score is driven primarily by strong cash generation and improving profitability, supported by constructive technical momentum. Valuation is reasonable with a solid dividend yield, while high leverage and earnings volatility, plus upcoming legacy/LOE headwinds (notably Eliquis timing) temper the overall rating.
To see Spark’s full report on BMY stock, click here.
More about Bristol-Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company focused on discovering, developing and delivering innovative medicines for serious diseases, with a portfolio spanning oncology, hematology, cardiovascular and immunology therapies. The company generates substantial revenue from a mix of growth products such as Opdivo, Reblozyl, Breyanzi and Camzyos, alongside a legacy portfolio facing rising generic competition.
Average Trading Volume: 12,287,601
Technical Sentiment Signal: Strong Buy
Current Market Cap: $117.6B
For detailed information about BMY stock, go to TipRanks’ Stock Analysis page.